 SAN FRANCISCO, March 02, 2021 GLOBE NEWSWIRE -- Nurix Therapeutics, Inc. Nasdaq: NRIX, a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares of common stock are being offered by Nurix. In addition, Nurix intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock. 